Dupilumab Treatment for Atopic Dermatitis Is Associated With Decreased Risk of Otitis Media and Related Surgical Procedures: A Retrospective Cohort Study.

IF 1.2 4区医学 Q3 DERMATOLOGY

Pediatric Dermatology Pub Date : 2025-07-16 DOI:10.1111/pde.16008

Matthew H Lanehart, Breanne Hayes, Zachary Zinn, David P Skoner

{"title":"Dupilumab Treatment for Atopic Dermatitis Is Associated With Decreased Risk of Otitis Media and Related Surgical Procedures: A Retrospective Cohort Study.","authors":"Matthew H Lanehart, Breanne Hayes, Zachary Zinn, David P Skoner","doi":"10.1111/pde.16008","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the risk of otitis media (OM) and related surgical procedures among population-based, propensity score-matched cohorts of patients with atopic dermatitis (AD) treated with dupilumab compared to those treated with pimecrolimus.Methods: The TriNetX research network was used to conduct a retrospective cohort study estimating the risk of all OM, nonsuppurative OM, suppurative OM, and subsequent surgical intervention in patients with AD treated with dupilumab compared to those treated with pimecrolimus, including an age-stratified analysis focused on pediatric patients. Cohorts were propensity score matched by age at index, current age, sex, race, other atopies, and exposure to tobacco smoke. 5-year Cox proportional hazards models with 95% confidence intervals were analyzed.Results: This study demonstrates that compared to those treated with pimecrolimus, AD patients treated with dupilumab have a significantly decreased 5-year risk of all OM (HR, 0.60; 95% CI, 0.54-0.67; p < 0.001), nonsuppurative OM (HR, 0.60; 95% CI, 0.52-0.70; p < 0.001), suppurative OM (HR, 0.61; 95% CI, 0.55-0.69; p < 0.001), and related surgical procedures (HR, 0.73; 95% CI, 0.58-0.90; p = 0.004), with similar results found among those < 18 years old.Conclusions: Overall, reduced risk of OM and related surgical procedures is observed in patients with AD treated with dupilumab compared to those treated with pimecrolimus.","PeriodicalId":19819,"journal":{"name":"Pediatric Dermatology","volume":" ","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/pde.16008","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the risk of otitis media (OM) and related surgical procedures among population-based, propensity score-matched cohorts of patients with atopic dermatitis (AD) treated with dupilumab compared to those treated with pimecrolimus.

Methods: The TriNetX research network was used to conduct a retrospective cohort study estimating the risk of all OM, nonsuppurative OM, suppurative OM, and subsequent surgical intervention in patients with AD treated with dupilumab compared to those treated with pimecrolimus, including an age-stratified analysis focused on pediatric patients. Cohorts were propensity score matched by age at index, current age, sex, race, other atopies, and exposure to tobacco smoke. 5-year Cox proportional hazards models with 95% confidence intervals were analyzed.

Results: This study demonstrates that compared to those treated with pimecrolimus, AD patients treated with dupilumab have a significantly decreased 5-year risk of all OM (HR, 0.60; 95% CI, 0.54-0.67; p < 0.001), nonsuppurative OM (HR, 0.60; 95% CI, 0.52-0.70; p < 0.001), suppurative OM (HR, 0.61; 95% CI, 0.55-0.69; p < 0.001), and related surgical procedures (HR, 0.73; 95% CI, 0.58-0.90; p = 0.004), with similar results found among those < 18 years old.

Conclusions: Overall, reduced risk of OM and related surgical procedures is observed in patients with AD treated with dupilumab compared to those treated with pimecrolimus.

查看原文本刊更多论文

杜匹单抗治疗特应性皮炎与中耳炎及相关外科手术风险降低相关：一项回顾性队列研究

目的：评估以人群为基础、倾向评分匹配的特应性皮炎（AD）患者接受杜匹单抗治疗与吡美莫司治疗的中耳炎（OM）和相关手术的风险。方法：TriNetX研究网络进行了一项回顾性队列研究，评估了与吡美莫司治疗相比，接受dupilumab治疗的AD患者发生所有OM、非化脓性OM、化脓性OM和后续手术干预的风险，包括针对儿科患者的年龄分层分析。队列的倾向得分与年龄指数、当前年龄、性别、种族、其他特征和吸烟暴露相匹配。采用95%置信区间的5年Cox比例风险模型进行分析。结果：本研究表明，与吡美莫司治疗的AD患者相比，dupilumab治疗的AD患者所有OM的5年风险显著降低(HR, 0.60；95% ci, 0.54-0.67；结论：总体而言，与吡美莫司相比，使用杜匹单抗治疗的AD患者发生OM和相关手术的风险降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

6.70%

发文量

269

审稿时长

1 months

期刊介绍： Pediatric Dermatology answers the need for new ideas and strategies for today''s pediatrician or dermatologist. As a teaching vehicle, the Journal is still unsurpassed and it will continue to present the latest on topics such as hemangiomas, atopic dermatitis, rare and unusual presentations of childhood diseases, neonatal medicine, and therapeutic advances. As important progress is made in any area involving infants and children, Pediatric Dermatology is there to publish the findings.